Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia

Lipton, 2006, Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry., Pediatr Blood Cancer, 46, 558, 10.1002/pbc.20642 Gustavsson, 1997, Diamond-Blackfan anaemia: Genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb., Nat Genet, 16, 368, 10.1038/ng0897-368 Draptchinskaia, 1999, The ribosomal protein S19 gene is mutated in Diamond-Blackfan anemia., Nat Genet, 21, 169, 10.1038/5951 Gazda, 2001, Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease., Blood, 97, 2145, 10.1182/blood.V97.7.2145 Borgna-Pignatti, 2005, Survival and complications in thalassemia., Ann N Y Acad Sci, 1054, 40, 10.1196/annals.1345.006 Piga, 2005, Deferiprone: New insight., Ann N Y Acad Sci, 1054, 169, 10.1196/annals.1345.019 Andersson, 2002, Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia., Lancet, 360, 516, 10.1016/S0140-6736(02)09740-4 Pennell, 2006, Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis., Blood, 107, 3738, 10.1182/blood-2005-07-2948 Wonke, 1998, Combined therapy with deferiprone and desferrioxamine., Br J Haematol, 103, 361, 10.1046/j.1365-2141.1998.01002.x Piga, 2006, Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload., Haematologica, 91, 873 Cappellini, 2006, A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia., Blood, 107, 3455, 10.1182/blood-2005-08-3430 Neufeld, 2006, Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions., Blood, 107, 3436, 10.1182/blood-2006-02-002394 Anderson, 2001, Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload., Eur Heart J, 22, 2171, 10.1053/euhj.2001.2822 Olivieri, 1996, Orally active iron chelators in the treatment of iron overload., Curr Opin Hematol, 3, 125, 10.1097/00062752-199603020-00004 Cohen, 1998, A multi-center safety trial of the oral iron chelator deferiprone., Ann N Y Acad Sci, 850, 223, 10.1111/j.1749-6632.1998.tb10478.x Vlachos, 2001, Hematopoietic stem cell transplantation for Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry., Bone Marrow Transplant, 27, 381, 10.1038/sj.bmt.1702784 Alessandri, 2000, Diamond-blackfan anemia and cyclosporine therapy revisited., J Pediatr Hematol Oncol, 22, 176, 10.1097/00043426-200003000-00020 Olivieri, 1986, Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions., N Engl J Med, 314, 869, 10.1056/NEJM198604033141402 Chen, 2005, Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients., J Pediatr Hematol Oncol, 27, 651, 10.1097/01.mph.0000194019.95096.b6 Hoffbrand, 1989, Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial., Lancet, 2, 457, 10.1016/S0140-6736(89)90641-7 Müller, 2000, Irreversible aplastic anemia after treatment with deferiprone in a patient with Blackfan-Diamond anemia and hemochromatosis., Blood, 96 Giri, 2000, Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia., Br J Haematol, 108, 167, 10.1046/j.1365-2141.2000.01796.x Cohen, 2003, Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone., Blood, 102, 1583, 10.1182/blood-2002-10-3280